Holen Sie sich die Stockscreener-App
8.12
3.68%
-0.31
Handel nachbörslich:
8.10
-0.02
-0.25%
Schlusskurs vom Vortag:
$8.43
Offen:
$8.31
24-Stunden-Volumen:
122.65K
Relative Volume:
0.96
Marktkapitalisierung:
$42.95M
Einnahmen:
$858.00K
Nettoeinkommen (Verlust:
$-8.98M
KGV:
-39.44
EPS:
-0.2059
Netto-Cashflow:
$-29.81M
1W Leistung:
+1.00%
1M Leistung:
-25.57%
6M Leistung:
+76.92%
1J Leistung:
+125.56%
1-Tages-Spanne:
$8.00
$8.50
1-Wochen-Bereich:
$8.00
$9.245
52-Wochen-Spanne:
$1.7608
$11.49
Rallybio Corp Stock (RLYB) Company Profile
Firmenname
Rallybio Corp
Sektor
Branche
Telefon
203- 859-3820
Adresse
234 CHURCH STREET, NEW HAVEN
Compare RLYB vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
8.12 | 44.59M | 858.00K | -8.98M | -29.81M | -0.2059 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-04-10 | Eingeleitet | Wedbush | Outperform |
| 2022-12-09 | Eingeleitet | JP Morgan | Overweight |
| 2022-02-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-08-23 | Eingeleitet | Cowen | Outperform |
| 2021-08-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-08-23 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Rallybio Corp Aktie (RLYB) Neueste Nachrichten
Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? - The Malaysian Reserve
Setup Watch: Can Rallybio Corporation sustain earnings growth2026 Movers & Precise Entry and Exit Recommendations - baoquankhu1.vn
RLYB Technical Analysis & Stock Price Forecast - Intellectia AI
AI Stocks: Is Rallybio Corporation stock trending bullishWeekly Trade Report & Daily Price Action Insights - baoquankhu1.vn
Rallybio CMO Departs Amid Pending Candid Therapeutics Merger - TipRanks
Rallybio chief medical officer departs as company announces leadership change By Investing.com - Investing.com South Africa
Rallybio chief medical officer departs as company announces leadership change - Investing.com Australia
Rallybio (RLYB) CMO Steven Ryder exits as Candid Therapeutics merger proceeds - stocktitan.net
RLYB Should I Buy - Intellectia AI
RALLYBIO CORP (NASDAQ:RLYB) Passes Minervini Trend and High Growth Momentum Filters - ChartMill
Rallybio (NASDAQ:RLYB) Rating Increased to Hold at Wall Street Zen - Defense World
Rallybio to acquire Candid Therapeutics - MSN
Rallybio to acquire Candid Therapeutics in $505M merger deal - MSN
If You Invested $1,000 in Rallybio Corp (RLYB) - stocktitan.net
Here's Why We're Watching Rallybio's (NASDAQ:RLYB) Cash Burn Situation - 富途牛牛
Halper Sadeh LLC is Investigating Whether RLYB, TALK, UNF are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Tiny biotech Rallybio stock surges as $500 million-backed merger fuels investor optimism - msn.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations - marketscreener.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Rallybio CVRs Carry High Risk of Expiring Worthless Amid Uncertain Asset Monetization - TipRanks
Halper Sadeh LLC is Investigating Whether TALK, JTAI, RLYB are Obtaining Fair Deals for their Shareholders - The Norfolk Daily News
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB - GlobeNewswire Inc.
Rallybio Corporation 2025 10-K: Clinical-Stage Rare Disease Biotech, Pipeline, Partnerships, and Regulatory Overview - Minichart
RLYB Surges on Revenue and Merger Hype Why the Stock Still Dropped - Bitget
Stock Recap: What hedge funds are buying Rallybio CorporationPortfolio Value Summary & Weekly High Conviction Ideas - baoquankhu1.vn
Rallybio (NASDAQ: RLYB) to become Candid after merger, $505.5M financing - Stock Titan
Rallybio 2025 10-K: $0.858M Revenue, $(8.98)M Net Loss - TradingView
Rallybio (NASDAQ: RLYB) plans Candid merger, $505.5M financing and CVR structure - Stock Titan
Rallybio: Net loss improved to $9.0 million in 2025 amid a pending merger, asset sale, and cost reductions - TradingView
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Candid Merging Into Public Market - San Diego Business Journal
RLYB Q4'25 Earnings: EPS estimate is (1.24) USD - TradingView
Retail Surge: Will Rallybio Corporation benefit from current market trendsNew Guidance & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Energy Moves: Can Rallybio Corporation generate free cash flowJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Rallybio Completes Key FNAIT Risk Study, Laying Groundwork for Future Market Moves - TipRanks
Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? - PR Newswire
Geopolitics Watch: Whats the profit margin of Rallybio CorporationWeekly Risk Report & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Brokerages Set Rallybio Corporation (NASDAQ:RLYB) Price Target at $40.00 - Defense World
Rallybio (RLYB) Expected to Announce Earnings on Thursday - MarketBeat
$105M for Starface pimple patches, humanoid robot maker eyes €1B and Rallybio's reverse merger - Axios
Candid Therapeutics to Merge with Rallybio in Reverse Merger - themiddlemarket.com
Rallybio Investor Alert: Merger Investigation Launched - National Today
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation – RLYB - Weekly Voice
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio CorporationRLYB - The AI Journal
Candid lists via Rallybio reverse merger, adds $505m financing - The Pharma Letter
Candid Therapeutics: $505 Million Financing And Merger With Rallybio To Advance Autoimmune T-Cell Engager Pipeline - Pulse 2.0
TPG group shows 7.2% Rallybio (RLYB) stake and supports Candid merger - Stock Titan
RLYB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rallybio merger deal includes $50M breakup fee, $200M financing floor - Hartford Business Journal
Latham & Watkins Advises on US$505 Million Financing in Connection With Rallybio-Candid Therapeutics Merger - Legal Desire Media and Insights
Rallybio, Candid Therapeutics announce merger agreement - TipRanks
Finanzdaten der Rallybio Corp-Aktie (RLYB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):